MDR-and CYP3A4-mediated drug-herbal interactions

Abstract

Abstract: According to recent epidemiological reports more and more people, both healthy and ill, use all kinds of Chinese herbal medicine during their lifetime.As the increasing combined usage of Chinese herbal medicine with prescription drugs, it draws lots of attentions on the therapeutic activity due to possible drug-herb interaction. It is known that P-glycoprotein (P-gp)together with cytochrome P450 3A4 (CYP3A4)leads to a highly efficient barrier for many orally absorbed drugs.Meanwhile, more than 50% of the clinical drugs are metabolized by CYP3A4 or transported by P-gp.Hence, more attention should be paid to MDR-and CYP3A4-mediated drug-herbal interactions.This survey discusses the key-factors of drug-herbal interaction as well.

Key words: P-glycoprotein, CYP3A4, prescribed drug, herb, bioavailability

CLC Number:

R968
R969

MAO Xiao-qin, XIE Hai-tang, ZHOU Hong-hao. MDR-and CYP3A4-mediated drug-herbal interactions[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(7): 728-734.

References

1 Sparreboom A, Danesi R, Ando Y, et al.Pharmacogenomics of ABC transporters and its role in cancer chemotherapy[J].Drug Resist Updat, 2003;6:71-84.
2 Thiebaut F, Tsuruo T, Hamada H, et al.Cellular localization of the multidrug resistance gene product P-gly coprotein in normal human tissues[J].Proc Natl Acad Sci USA, 1987;84:7735-7738.
3 de Lannoy IA, SilvermanM.TheMDR1 gene product P-gly coprotein, mediates the transport of the cardiac gly coside, digoxin [J].Biochem Biophys Res Commun, 1992;189:551-557.
4 Fromm MF.P-glycoprotein:a defense mechanism limiting oral bioavailability and CNS accumulation of drugs[J].Int J Clin Pharmacol Ther, 2000;38:69-74.
5 Sakaeda T, Nakamura T, Okumura K.MDR1 genotype-related pharmacokinetics and pharmacodynamics[J].Biol Pharm Bull, 2002;25:1291-1400.
6 Kim RB, Fromm MF, Christoph W, et al.The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV21 protease inhibitors[J].J Clin Invest, 1998;101:289-294.
7 Bosch I, Croop J.P-glycoprotein, multidrug resistance and cancer[J].Biochim Biophys Acta, 1996;1288:F37-F54.
8 Borst P, Evers R, Kool M, et al.A family of drug transporters:the multidrug resistance-associated proteins[J].J Natl Cancer Inst, 2000;92:1295-1302.
9 Hyde SC, Emsley P, HartshornMJ, et al.Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport[J].Nature, 1990;346:362-365.
10 Ambudkar SV, Dey S, Hry cyna CA, et al.Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].Annu Rev Pharmacol Toxicol, 1999;39:361-398.
11 Lin JH, Yamazaki M.Role of P-glycoprotein in pharmacokinetics: clinical implications[J].Clin Pharmacokinet, 2003;42:59-98.
12 Yu DK.The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions[J].J Clin Pharmacol, 1999;39:1203-1211.
13 Chiou WL, Chung SM, Wu TC.Potential role of P-glycoprotein in affecting hepatic metabolism of drugs[J].Pharm Res, 2000; 17:903-905.
14 Katoh M, Nakajima M, Yamazaki H, et al.Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoproteinmediated transport[J].Eur J Pharm Sci, 2001;12:505-513.
15 Wacher VJ, Salphati L, Benet LZ, et al.Active secretion and enterocytic drug metabolism barriers to drug absorption[J].Adv Drug Deliv Rev, 2001;46:89-102.
16 Weinstein RS, Kuszak JR, Kluskens LF, et al.P-glycoproteins in pathology:the multidrug resistance gene family in humans[J].Hum Pathol, 1990;21:34-48.
17 朱冰.3A 的分子机制研究[J].中国药理学通报, 2000; 16:614-617.
18 Patel J, Mitra AK.Strategies to overcome simultaneous P-glycoprotein mediatedefflux and CYP3A4 mediated metabolism of drugs[J].Pharmacogenomics, 2001;2:401-415.
19 Relling MV.Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs[J]? Ther Drug Monit, 1996;18:350-356.
20 Slaughter RL, Edwards DJ.Recent advances:the cytochrome P-450 enzymes[J].Ann Pharmacother, 1995;29:619-624.
21 Schuetz EG, Beck WT, Schuetz JD.Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells[J].Mol Pharmacol, 1996;49:311-318.
22 Gallicano K, Foster B, Choudhri S.Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers[J].Br J Clin Pharmacol, 2003; 55:199-202.
23 Piscitelli SC, Burstein AH, Welden N, et al.The effect of garlic supplements on the pharmacokinetics of saquinavir[J]. Clin Infect Dis, 2002;34:234-238.
24 Hsu A, Granneman GR, Bertz RJ.Ritonavir.Clinical pharmacokinetics and interactions with other anti-HIV agents[J].Clin Pharmacokinet, 1998;35:275-291.
25 Brinker F.Herb Contraindications and Drug Interactions[M]. Sandy, Oregan:Eclectic Medical Publications, 1998.
26 Izzo AA, Ernst E.Interactions between herbal medicines and prescribed drugs:a systematic review[J].Drugs, 2001;61: 2163-2175.
27 Moore LB, Goodwin B, Jones SA, et al.St.John's wort induces hepatic drug metabolism through activation of the pregnane X receptor[J].Proc Natl Acad Sci USA, 2000;97:7500-7502.
28 Durr D, Stieger B, Kullak-Ublick GA, et al.St.John's wort induces intestinal P-glycoprotein MDR1 and intestinal and hepatic CYP3A4[J].Clin Pharmacol Ther, 2000;68:598-604.
29 Perloff MD, von Moltke LL, Stormer E, et al.Saint John's wort:an in vitro analysis of P-gly coprotein induction due to extended exposure[J].Br J Pharmacol, 2001;134:1601-1608.
30 Bistrup C, Nielsen FT, Jeppesen UE, et al.Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients[J].Nephrol Dial Transplant, 2001;16:373-377.
31 Soldner A, Christians U, Susanto M, et al.Grapefruit juice activates P-glycoprotein-mediated drug transport [J].Pharm Res, 1999;16:478-485.
32 Bailey DG, Malcolm J, Arnold O, et al.Grapefruit juice-drug interactions[J].Br J Clin Pharmacol, 1998;46:101-110.
33 Liao BS, Newmark H, Zhou RP.Neuroprotective effects of ginseng totalsaponin and ginsenosides Rb1 and Rg1 on spinal cord neurons in vitro[J].Exp Neurol, 2002;173:224-234.
34 Park JD, Kim DS, Kwon HY, et al.Effects of ginseng saponin on modulation of multidrug resistance[J].Arch Pharm Res, 1996;19:213-218.
35 Kim SW, Kwon HY, Chi DW, et al.Reversal of P-glycoprotein-mediated multidrug resistance by ginsenosideRg(3)[J]. Biochem Pharmacol, 2003;65:75-82.
36 Harkey MR, Henderson GL, Gershwin ME, et al.Variability in commercial ginseng products:An analysis of 25 preparations [J].Am J Clin Nutr, 2001;73:1101-1106.
37 Ammon HPT, WahlMA.Pharmacology of Curcuma longa[J]. Planta Med, 1991;57:1-7.
38 Anuchapreeda S, Leechanachai P, Smith MM, et al.Modulation of P-gly coprotein expression and function by curcumin in multidrug-resistant human KB cells[J].Biochem Pharmacol, 2002;64:573-582.
39 Smith M, Lin KM, Zheng YP.An open trial of nifedipine-herb interactions:Nifedipine with St.John's wort, ginseng or Ginkgo biloba[J].Clin Pharmacol Ther, 2001;69:P86.
40 Chavez ML, Chavez PI.Ginkgo (part 1):history, use, and pharmacologic properties[J].Hosp Pharm, 1998;33:658-672.
41 Rosenblatt M, Mindel J.Spontaneous hyphema associated with ingestion of Ginkgobiloba extract[J].N Engl J Med, 1997; 336:1108.
42 Piscitelli SC, Formentini E, Burstein AH, et al.Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers [J].Pharmacotherapy, 2002;22:551-556.
43 Brinker F.Herb Contraindications and Drug Interactions[M]. Sandy, Oregan:Eclectic Medical Publications, 1998.
44 Patel J, Buddha B, Dey S, et al.In vitro interaction of the HIVprotease inhibitor ritonavir with herbal constituents:changes in Pgp and CYP3A4 activity[J].Am J Ther, 2004;11:262-277.
45 Kent UM, Aviram M, Rosenblat M, et al.The licorice root derived isoflavan glabridin inhibits the activities of human levels of amitriptyline and its metabolites on comedication cytochrome P450S 3A4, 2B6, and 2C9[J].Drug Metab Dispos, 2002;30: 709-715.
46 Paolini M, Pozzetti L, Sapone A, et al.Effect of licorice and glycyrrhizin on murine liver CYP-dependent monooxygenases [J].Life Sci, 1998;62:571-582.

[1]	JING Yongshuai, ZHANG Yuwei, WU Lanfang, ZHANG Ruijuan, MA Yunfeng, ZHANG Danshen. Research progress on extraction methods and pharmacological activities of polysaccharide from traditional Chinese herb compound [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 462-468.
[2]	LI Zhihui, LIU Jingyan, QIU Wen, CHEN Hong. Bioequivalence of fluconazole capsules in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 910-915.
[3]	ZHANG Shengpeng, MIU Dongdong, LIU Dingfeng, ZHU Xiaohong, ZHANG Chao, CHEN Yunyu, LIU Xiaoping. Hepatic toxicity and pharmacodynamic effects of paracetamol and chlorphenamine maleate with three herb extracts capsules [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 489-495.
[4]	LIU Li, PENG Jinfu, GUO Chengxian, YANG Xiding, LI Haigang, YANG Guoping. Regulative effects of miR-150 on CYP3A4 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 749-754.
[5]	ZHANG Jingxian, CHEN Tao, ZHANG Xiangqi, SHI Meizhi, CHEN Junjun, ZHANG Kezhi, YANG Jiao, GUO Cheng, WANG Laiyou, HAN Yonglong. Inhibition effects of Danhong injection on three transporters in human primary hepatocytes in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 389-394.
[6]	HUANG Wei, HU Xiao. Study on the mechanism of cytochrome P450 3A4 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 223-229.
[7]	TANG Xia, XIN Hua-wen, LI Wei-liang, OUYANG Meng. Study of the effects of Berberine on CYP3A4 and P-gp in HepG2 cells and its mechanism in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 7-13.
[8]	SHEN Han-yuan, HAO Hai-ping, WANG Guang-ji. Current advancement on pharmacokinetics study of herbal injection prescription [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 937-942.
[9]	LIU Li-ya, HAN Yong-long, YU Qi, ZHU Jin-hui, GUO Cheng. In vitro inhibition of 4 anti-tumor traditional Chinese medicine injections on activities of 7 main cytochrome P450s in human liver microsome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(5): 522-527.
[10]	OUYANG Cang-hong, XIE Juan. Study on the relationship between the MDR1 and CYP3A genetic polymorphisms and serum digoxin concentration in 111 patients with chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 291-296.
[11]	YU Jian, XIN Yan-fei , GU Li-qiang, GAO Hai-yan, ZHANG Sheng, YOU Zhen-qiang, WEN Lei, CHEN Guo-can, CHEN Yun-xiang, XUAN Yao-xian. Effects of Lycium barbarum Polysaccharide on doxorubicin pharmacokinetics in dogs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 246-253.
[12]	ZOU Quan-fei, LU Rong, FAN Hui-rong, ZHAO Guang-rong, ZHANG Tie-jun, SI Duan-yun. Study of pharmacokinetics and bioavailability of scicinib in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 254-259.
[13]	WANG Yan, YANG Guo-ping, GUO Cheng-xian, PEI Qi, ZHANG Ran-ran, HUANG Lu. Plasma Double-peak Phenomenon Following Oral Administration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 341-345.
[14]	WANG Pei-pei, XU Du-juan, HUANG Can, XU Wen-ke, LUAN Jia-jie. Reversal of human hepatic cancer multidrug resistance is induced by AstragalosideⅡ in BEL-7402/FU cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 139-144.
[15]	WANG Rong, CHEN Ke-rui, LIU Xiao-mei, TANG Hui-en, HE Zhen-yu. Investigation of the rs28371759 polymorphism of CYP3A4 gene in Guangdong population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1255-1258.